PFA
SRNE

Pathway Financial Advisers’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Pathway Financial Advisers’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30
Closed -$27 – 568
2022
Q4 		$27 Buy
+30
New +$40 ﹤0.01% 558

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Pathway Financial Advisers's SRNE Position: Q1 2023 in Review

Pathway Financial Advisers sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 30 shares — an estimated $27 sold.

Pathway Financial Advisers first reported a position in SRNE in Q4 2022 and held it in 1 quarter. The position peaked at $27 in Q4 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Pathway Financial Advisers reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Pathway Financial Advisers sold 30 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $27.
  • Pathway Financial Advisers first reported a position in Sorrento Therapeutics, Inc. in Q4 2022 and held it in 1 quarter.
  • Pathway Financial Advisers's Sorrento Therapeutics, Inc. position peaked at $27 in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Pathway Financial Advisers's 13F filing for Q1 2023, filed 19 Jul 2024.